Articles by tag: pediatric-diabetes

FDA to Review Afrezza: First Needle-Free Insulin for Children

On May 29, 2026, the FDA will decide on Afrezza inhaled insulin for children aged 4–17. Learn why this is a market shift and a chance for a needle-free life. Read the analysis.

FDA to Review Inhaled Insulin Afrezza for Children

On May 29, FDA will decide on needle-free insulin Afrezza for children aged 4–17. Learn why this is a paradigm shift in diabetology. Detailed analysis in the article.